Cell therapy solutions in a heartbeat
Based in Stockholm, Procella Therapeutics is an early stage biotechnology company focused on developing cardiac stem cell technology leveraging research from Harvard University and Karolinska Institutet with the aim of treating heart failure. Procella is collaborating with AstraZeneca to take our first cellular product candidate from pre-clinical stage to first-in-human studies and, if successful in early trials, further development towards commercial manufacture.
Procella Therapeutics started in 2018 upon a vision to create the next generation of cell-based therapies for patients running out of options.
Our first mission is to develop a cardiac stem cell therapy for patients with advance heart failure and to do this with focus, drive, persistence, creativity, integrity, and inclusiveness.
Why cardiovascular disease?
Cardiovascular disease, and heart failure specifically, is one of the leading causes of morbidity and mortality globally and one of the highest economical health care burden. Globally, heart failure affects 64 million people globally (Lancet. 2017 Sep;390(10100):1211-1259.) In the United States, 5 million people in the United States suffer from a failing heart, and the disease costs the US health system over $30 billion per year. (Card Fail Rev. 2017 Apr; 3(1): 7–11.)
When the heart fails, it cannot pump blood efficiently through the body and supply the body with oxygen. A common cause of this damage is heart attacks, during which the heart blood vessels are blocked, depriving the heart muscle of oxygen, and leading to scarring and heart cell death. Procella’s cell technology aims to repair damaged hearts, and in early pre-clinical studies has been shown to have engraftment capability to create new muscle in hearts damaged from a heart attack. (Foo et al.)
A unique cardiac progenitor cell technology –our current core technology- with demonstrated potential to regenerate muscle of damaged heart in animal models. We are optimizing the manufacturing process and quality of PROC-001 and collaborating with AstraZeneca as we advance towards First-in-Human studies.
To achieve our vison Procella comprises a talented team of multidisciplinary backgrounds ranging from stem cell biology to bioprocess and analytical development, and from bioinformatics to cardiology.
Are you looking for a career in cell therapy? We are continuously looking for passionate and talented individuals to join our team. Send your CV and cover letter to email@example.com. Check the current job vacancies from our LinkedIn page.
Alfred Nobels Allé 150
146 48 Tullinge